bioAffinity furnishes Sept. 2026 investor deck

Q: What did bioAffinity Technologies (BIAF) announce in this Form 8-K?

bioAffinity Technologies furnished investor presentation materials as Exhibit 99.1. Management intends to use these materials in presentations about the company’s operations and performance, including at the H.C. Wainwright 28th Annual Global Investment Conference in September 2026.

Q: How is the bioAffinity Technologies (BIAF) presentation treated under SEC rules?

The company states the presentation materials are furnished, not filed, under Regulation FD. As a result, they are not subject to Section 18 liability of the Exchange Act and are not automatically incorporated by reference into other Securities Act or Exchange Act filings.

Q: What exhibit did bioAffinity Technologies (BIAF) include with this 8-K?

The filing includes Exhibit 99.1, described as “Presentation Materials – September 2026,” and Exhibit 104, the Cover Page Interactive Data File embedded within the XBRL document.

Q: For what event will bioAffinity Technologies (BIAF) use these materials?

Management plans to use the materials at the H.C. Wainwright 28th Annual Global Investment Conference, which is scheduled for September 14–16, 2026, and may also use them in other presentations about the company’s operations and performance.

Q: Does this bioAffinity Technologies (BIAF) 8-K contain new financial results?

No. The 8-K describes presentation materials used for investor communications under Regulation FD. It does not present earnings data or new financial statements within the text provided.

bioAffinity Technologies is furnishing investor presentation materials for use at the H.C. Wainwright Global Investment Conference under a Regulation FD disclosure.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. (BIAF) reported that management has prepared investor presentation materials covering the company’s operations and performance, which may be used from time to time, including at the H.C. Wainwright 28th Annual Global Investment Conference taking place September 14–16, 2026.

The presentation materials are furnished as Exhibit 99.1 under a Regulation FD disclosure and are expressly designated as “furnished” rather than “filed,” meaning they are not subject to certain Exchange Act liabilities and are not automatically incorporated by reference into other Securities Act or Exchange Act filings.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Conference dates: September 14–16, 2026 Exhibit 99.1: Presentation Materials – September 2026 Par value per share: $0.007 per share

3 metrics

Conference dates September 14–16, 2026 Dates of the H.C. Wainwright 28th Annual Global Investment Conference where the materials will be used

Exhibit 99.1 Presentation Materials – September 2026 Investor presentation furnished with the 8-K

Par value per share $0.007 per share Par value of bioAffinity Technologies common stock

Key Terms

Regulation FD, emerging growth company, Presentation Materials, furnished as Exhibit 99.1

4 terms

Regulation FD regulatory

"Item 7.01. Regulation FD Disclosure."

Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Presentation Materials financial

"has prepared presentation materials (the “Presentation Materials”)"

Presentation materials are the visual and written tools used to communicate information clearly and effectively, such as slides, charts, reports, or handouts. They help convey key ideas, data, or plans to an audience, making complex information easier to understand—much like a map guides a traveler through unfamiliar territory. For investors, well-prepared presentation materials provide essential insights into a company's performance, strategy, or prospects.

furnished as Exhibit 99.1 regulatory

"The Presentation Materials are furnished as Exhibit 99.1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did bioAffinity Technologies (BIAF) announce in this Form 8-K?

bioAffinity Technologies furnished investor presentation materials as Exhibit 99.1. Management intends to use these materials in presentations about the company’s operations and performance, including at the H.C. Wainwright 28th Annual Global Investment Conference in September 2026.

How is the bioAffinity Technologies (BIAF) presentation treated under SEC rules?

The company states the presentation materials are furnished, not filed, under Regulation FD. As a result, they are not subject to Section 18 liability of the Exchange Act and are not automatically incorporated by reference into other Securities Act or Exchange Act filings.

What exhibit did bioAffinity Technologies (BIAF) include with this 8-K?

The filing includes Exhibit 99.1, described as “Presentation Materials – September 2026,” and Exhibit 104, the Cover Page Interactive Data File embedded within the XBRL document.

For what event will bioAffinity Technologies (BIAF) use these materials?

Management plans to use the materials at the H.C. Wainwright 28th Annual Global Investment Conference, which is scheduled for September 14–16, 2026, and may also use them in other presentations about the company’s operations and performance.

Does this bioAffinity Technologies (BIAF) 8-K contain new financial results?

No. The 8-K describes presentation materials used for investor communications under Regulation FD. It does not present earnings data or new financial statements within the text provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/11/2026 - 08:31 AM Accepted by SEC EDGAR 09/11/2026 - 08:30 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 11, 2026

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-41463

46-5211056

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

(210) 698-5334

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	Trading Symbols	Name of each exchange on which registered
Common Stock, par value $0.007 per share	BIAF	The Nasdaq Stock Market LLC
		(Nasdaq Capital Market)

Warrants to purchase Common Stock	BIAFW	The Nasdaq Stock Market LLC
		(Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

bioAffinity Technologies, Inc., a Delaware corporation, (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time in presentations about the Company’s operations and performance, including at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14, 2026, through September 16, 2026. The Presentation Materials are furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K are furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit Number		Description
99.1		Presentation Materials – September 2026
104		Cover Page Interactive Data File (embedded within the XBRL document)

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.